PARG-IN-4
PARG-IN-4 (Formula (A) ) is an orally available PARG inhibitor (EC50=1.9 nM) with cell membrane permeability. PARG-IN-4 can effectively inhibit tumor growth in mouse models. PARG-IN-4 can be used in cancer research[1].
Product Specifications
CAS Number
[2988890-20-4]
UNSPSC
12352005
Target
Apoptosis; Poly (ADP-ribose) Glycohydrolase (PARG)
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/parg-in-4.html
Purity
98.86
Solubility
DMSO : 20 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
CC1(CC1)NS(=O)(C2=CC(N3C[C@@H](N[C@H](C3)C)C)=C(C=NN4C5=NN=C(C(F)F)S5)C4=C2)=O
Molecular Formula
C20H25F2N7O2S2
Molecular Weight
497.59
References & Citations
[1]Paul A Barsanti, et al. Piperazine substituted indazole compounds as inhibitors of parg. Patent WO2023183850A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 4
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Ubiquitin (FLJ25987, MGC8385, Polyubiquitin B, RPS27A, UBA52, UBA80, UBC, UBCEP1, UBCEP2, Ubiquitin B, UBB) (HRP)
Ubiquitin (FLJ25987, MGC8385, Polyubiquitin B, RPS27A, UBA52, UBA80, UBC, UBCEP1, UBCEP2, Ubiquitin B, UBB) (HRP)
